GlassScriptPhysician profile
Tabetha Fleszar
NPI 1649946120
$2,364.86
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.44 · 2022: $1,295 · 2023: $994 · 2024: $35.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $736.00 | 2022-2024 | Interstim |
| Myriad Genetic Laboratories, INC. | $194.94 | 2021-2023 | Prolaris, Myrisk |
| Astellas Pharma US INC | $177.09 | 2022-2023 | Myrbetriq |
| Dendreon Pharmaceuticals LLC | $165.87 | 2022-2023 | Provenge |
| Myovant Sciences INC. | $144.55 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $122.60 | 2022-2023 | Xiaflex |
| Abbvie INC. | $108.93 | 2023 | |
| Janssen Biotech, INC. | $95.83 | 2022-2023 | Erleada |
| Astrazeneca Pharmaceuticals LP | $84.83 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $69.92 | 2022 | |
| Procept Biorobotics Corporation | $65.33 | 2022 | |
| Sumitomo Pharma America, INC. | $44.88 | 2023 | Gemtesa |
| Axonics, INC. | $44.29 | 2022 | |
| Urovant Sciences INC | $42.72 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.10 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $35.38 | 2023 | |
| Merck Sharp & Dohme LLC | $31.21 | 2022-2023 | Lynparza, Keytruda |
| Boston Scientific Corporation | $29.88 | 2023 | Lithovue, Rezum Generator |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.83 | 2024 | Lifevest |
| Antares Pharma, INC. | $21.80 | 2023 | Tlando, Xyosted, Nocdurna |
| Urogen Pharma, INC. | $17.23 | 2022 | |
| Pfizer INC. | $16.70 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.80 | 2023 | Seglentis |
| Coloplast Corp | $13.41 | 2023 | Speedicath |
| Halozyme INC | $13.14 | 2023 | |
| 180 Medical, INC. | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabetha Fleszar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.